A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Chen, Yuan , Ph.D. Bookmark and Share

Yuan Chen, Ph.D. Research

 
Ubiquitin-like Modifications
Our current research interest is in protein modifications by a family of small proteins known as ubiquitin and its homologues. These modifications control life spans, trafficking, assembly and enzymatic activities of cellular proteins, and are important in nearly every aspect of biological functions. We employ a combination of structural, biochemical, molecular and cellular biological methods to understand these processes in cellular regulation and disease pathogenesis. Specific areas of interest are outlined below.

The Role of SUMOylation in Oncogenesis
Post-translational modifications by the small ubiquitin-like modifiers (SUMO) are important in oncogenesis and cellular response to DNA damage. Recent findings indicate that the key oncogenic pathways driven by Myc and KRas are dependent on, or addicted to, SUMOylation. For example, knocking down of the gene encoding the catalytic subunit of the SUMO activating enzyme (SAE), SAE2, has the strongest synthetic lethal interaction with Myc hyperactivation. We are investigating the molecular mechanisms underlying the synthetic lethality of SUMOylation with Myc hyperactivation and KRas mutations. In addition, we are investigating the structure-activity relationship of how the inhibitors interact with the SAE and inhibit its enzymatic activity, and use this information to guide further improvement of the inhibitors. These studies could potentially improve treatment of many cancers, as overexpression of Myc is estimated to contribute to 70 percent of all human cancers, and KRas is also frequently mutated in human cancers.

SUMO Modifications and HIV Replication
SUMO-specific proteases (SENP) regulate post-translational modifications by SUMO through catalyzing the maturation of SUMO precursors and the removal of SUMO from modified proteins. Small molecule inhibitors of SENPs that function in cells would be valuable tools for elucidating the functions of SENPs. We have recently identified a family of small molecule inhibitors of SENPs that inhibit de-SUMOylation activities in cells. Coincidently, these small molecules had been shown to confer anti-HIV activities in a National Cancer Institute antiviral screen, although the cellular targets and the mechanism of inhibition of HIV were unknown. We are investigating the molecular mechanism of how SUMOylation is involved in HIV life cycle. In addition, we are conducting the structure-activity relationship studies of how these inhibitors interact with the SENPs and inhibit their enzymatic activity, and use this information to develop improved inhibitors. Furthermore, we are interested in exploiting this pathway to develop a potential strategy for a cure of HIV by allowing the immune system to target HIV infected cells without producing infectious virus.

NMR-based Metabolomics
Metabolic activity is a reflection of cellular functions. Our laboratory utilizes nuclear magnetic resonance (NMR) spectroscopy as tools for metabolomic studies, that is, global analysis of metabolic activities. Our goal is to provide information on cellular pathways to understand metabolic dysfunctions of cancer cells.

Application of NMR Methods in Drug Discovery
We are collaborating with several other laboratories with expertise in synthetic chemistry, molecular biology and medical oncology to develop new therapeutics for cancer. State-of-the-art NMR methods are employed to provide information on protein-ligand interactions at an atomic resolution; information that is critical for the rational design of new therapeutics.
 
Representative Publications:
 
Gold nanoparticles as a platform for creating a multivalent poly-SUMO chain inhibitor that also augments ionizing radiation
YJ Li, AL Perkins, Y Su, Y Ma, L Colson, DA Horne, Y Chen
Proceedings of the National Academy of Sciences 109 (11), 4092-4097, 2012
 
The intrinsic affinity between E2 and the Cys domain of E1 in ubiquitin-like modifications
J Wang, W Hu, S Cai, B Lee, J Song, Y Chen
Molecular cell 27 (2), 228-237, 2007
 
Identification of a SUMO-binding motif that recognizes SUMO-modified proteins
Jing Song, Linda K Durrin, Thomas A Wilkinson, Theodore G Krontiris, Yuan Chen
Proceedings of the National Academy of Sciences of the United States of America, 101 (40), 14373-14378, 2004
 
More publications can be found at:
http://scholar.google.com/citations?user=zgAR9fsAAAAJ&hl=en
 

Yuan Chen, Ph.D. Facilities

NMR Facility
 
Computers and Software
  • Six Linex workstations
  • Two multi-processor servers
  • Software include: InsightII, FELIX, NMRVIEW, NMRDRAW, PIPE, MOLMOL, DYANA, CNS, ARIA, HADDOCK and AMBER.
 
Other Shared Equipment
  • Isothermal titration calorimeter
  • Jasco CD instrument
  • Automated Applied Biosystems (AB) Procise Protein Sequencing System for N-terminal Edman degradation
  • A Perkin Applied Biosystems Procise C-terminal sequencer and a Hewlett Packard C-terminal sequencer
  • Dionex AAA Direct amino acid analyzer
  • HPLC systems suitable for narrow-bore and microcapillary chromatography and equipped for detection of peptides at 214 nm as well as variable wavelength fluorescence detection
  • Pharmacia FPLC for protein purification
  • Perkin-Elmer FTIR
  • Hitachi UV/VIS Spectrophotometer
  • Pharmacia BIAcoreTM System
  • PerSeptive Biosystems BioCAD/SPRINT
  • Bio-Rad scanning Densitometer
  • Three Thermo Finnigan LCQ family ion traps (two Classic and one Deca) equipped with electrospray/LC sources.
  • An Applied Biosystems Mariner electrospray (ES) Orthogonal TOF spectrometer
  • Applied Biosystems Voyager DE STR MALDI-TOF spectrometer
  • Scintillation and gamma counters
  • Wallac Micro Beta counter
  • Tomtec 96-well plate harvester
 

Lab Members

 
Current Lab Members

Shannon Maldonado
Senior Administrative Analyst
 
Ramir Vega
Research Associate
 
Grace Aldana-Masangkay, Ph.D.
Research Fellow
 
Aileen Alontaga, Ph.D.
Research Fellow
 
Nigus D Ambaye, Ph.D.
Research Fellow

Chih-Hong Chen, Ph.D.
Research Fellow

Li Du, Ph.D.
Research Fellow
 
Yi-Jia Li, Ph.D.
Staff Scientist
 
Alumni

Postdoctoral fellows
Yate-Ching Yuan, Ph.D.
Director of the Bioinformatic Core Facility at Beckman Research Institute of City of Hope

Maria Victoria Botuyan, Ph.D.
Staff scientist at Mayo Clinic, MN, USA

Jerry Hu, Ph.D.
Manager, Materials Research Laboratory Spectroscopy Facility, UC Santa Barbara

Donghai Lin, Ph.D.
Professor at Shanghai Institute of Materia Medica, Chinese Academy of Sciences. 

Suhkmann Kim, Ph.D.
Associate Professor at Pusan National University, Korea. 

Sheng Cai, Ph.D.
Director of the NMR laboratory at Marquette University, Wisconsin, USA

Lingyang Zhu, Ph.D.
Senior Scientist, Array BioPharma Inc. Boulder, CO

Thomas Wilkinson, Ph.D.
Staff Scientist, UCLA

Xuanjun Ai, Ph.D.
Postdoctoral fellow with Dr. Charalampos Kalodimos at Rutgers University
 
Ikenna Madu, Ph.D.
Scientist Kineta, Inc, Seattle, WA
 
Yang Su, Ph.D.
Beijing, China
 
Jianghai Wang, Ph.D.
Senior Scientist, BostonBiochem, MA, USA
 
Yifei Li, Ph.D.
NCI at Frederick, Frederick, MD
 
Graduate students
Ziming Zhang, Ph.D. (2004)
Director of the Nuclear Magnetic Resonance Core, University of South Florida

Jing Song, Ph.D. (2006)
Jing spent two years as a postdoctoral fellow with Professor Timothy Springer at Harvard Medical School, and now is group leader at BioDuro.

Khue Truong, Ph.D. (2012)
Post doctoral fellow at UCLA.

Research technicians
Qin Liu, M.S., Biomolecular NMR Facility manager, Department of Biochemistry, University of Western Ontario, Canada

Candace Seu, Ph.D. student, UC San Diego

Lisa Fukui, M.D/Ph.D. student, University of Illinois at Urbane Champion

Brian Lee, medical student, SUNY Stony Brook

Larry Tong, medical student, University of Nebraska

Steven Wong, medical student, UCLA
 

Yuan Chen, Ph.D. NvMap Agreement Download

Academic (nonprofit) License Agreement
 
Please send two signed originals of the license agreement to:
 
City of Hope
1500 East Duarte Road
Duarte, California 91010
Attn.:  Director, Office of Technology Licensing
Fax: 626-301-8175
 
With a copy to:
 
Dr. Yuan Chen
Department of Molecular Medicine
City of Hope
1500 East Duarte Road
Duarte, California 91010
Fax: 626-301-8186
 
Industry License Agreement
 
For more information please contact:
 
Matthew Grunseth, M.B.S.
Technology Licensing Manager
mgrunseth@coh.org
 

Chen, Yuan , Ph.D.

Yuan Chen, Ph.D. Research

 
Ubiquitin-like Modifications
Our current research interest is in protein modifications by a family of small proteins known as ubiquitin and its homologues. These modifications control life spans, trafficking, assembly and enzymatic activities of cellular proteins, and are important in nearly every aspect of biological functions. We employ a combination of structural, biochemical, molecular and cellular biological methods to understand these processes in cellular regulation and disease pathogenesis. Specific areas of interest are outlined below.

The Role of SUMOylation in Oncogenesis
Post-translational modifications by the small ubiquitin-like modifiers (SUMO) are important in oncogenesis and cellular response to DNA damage. Recent findings indicate that the key oncogenic pathways driven by Myc and KRas are dependent on, or addicted to, SUMOylation. For example, knocking down of the gene encoding the catalytic subunit of the SUMO activating enzyme (SAE), SAE2, has the strongest synthetic lethal interaction with Myc hyperactivation. We are investigating the molecular mechanisms underlying the synthetic lethality of SUMOylation with Myc hyperactivation and KRas mutations. In addition, we are investigating the structure-activity relationship of how the inhibitors interact with the SAE and inhibit its enzymatic activity, and use this information to guide further improvement of the inhibitors. These studies could potentially improve treatment of many cancers, as overexpression of Myc is estimated to contribute to 70 percent of all human cancers, and KRas is also frequently mutated in human cancers.

SUMO Modifications and HIV Replication
SUMO-specific proteases (SENP) regulate post-translational modifications by SUMO through catalyzing the maturation of SUMO precursors and the removal of SUMO from modified proteins. Small molecule inhibitors of SENPs that function in cells would be valuable tools for elucidating the functions of SENPs. We have recently identified a family of small molecule inhibitors of SENPs that inhibit de-SUMOylation activities in cells. Coincidently, these small molecules had been shown to confer anti-HIV activities in a National Cancer Institute antiviral screen, although the cellular targets and the mechanism of inhibition of HIV were unknown. We are investigating the molecular mechanism of how SUMOylation is involved in HIV life cycle. In addition, we are conducting the structure-activity relationship studies of how these inhibitors interact with the SENPs and inhibit their enzymatic activity, and use this information to develop improved inhibitors. Furthermore, we are interested in exploiting this pathway to develop a potential strategy for a cure of HIV by allowing the immune system to target HIV infected cells without producing infectious virus.

NMR-based Metabolomics
Metabolic activity is a reflection of cellular functions. Our laboratory utilizes nuclear magnetic resonance (NMR) spectroscopy as tools for metabolomic studies, that is, global analysis of metabolic activities. Our goal is to provide information on cellular pathways to understand metabolic dysfunctions of cancer cells.

Application of NMR Methods in Drug Discovery
We are collaborating with several other laboratories with expertise in synthetic chemistry, molecular biology and medical oncology to develop new therapeutics for cancer. State-of-the-art NMR methods are employed to provide information on protein-ligand interactions at an atomic resolution; information that is critical for the rational design of new therapeutics.
 
Representative Publications:
 
Gold nanoparticles as a platform for creating a multivalent poly-SUMO chain inhibitor that also augments ionizing radiation
YJ Li, AL Perkins, Y Su, Y Ma, L Colson, DA Horne, Y Chen
Proceedings of the National Academy of Sciences 109 (11), 4092-4097, 2012
 
The intrinsic affinity between E2 and the Cys domain of E1 in ubiquitin-like modifications
J Wang, W Hu, S Cai, B Lee, J Song, Y Chen
Molecular cell 27 (2), 228-237, 2007
 
Identification of a SUMO-binding motif that recognizes SUMO-modified proteins
Jing Song, Linda K Durrin, Thomas A Wilkinson, Theodore G Krontiris, Yuan Chen
Proceedings of the National Academy of Sciences of the United States of America, 101 (40), 14373-14378, 2004
 
More publications can be found at:
http://scholar.google.com/citations?user=zgAR9fsAAAAJ&hl=en
 

Facilities

Yuan Chen, Ph.D. Facilities

NMR Facility
 
Computers and Software
  • Six Linex workstations
  • Two multi-processor servers
  • Software include: InsightII, FELIX, NMRVIEW, NMRDRAW, PIPE, MOLMOL, DYANA, CNS, ARIA, HADDOCK and AMBER.
 
Other Shared Equipment
  • Isothermal titration calorimeter
  • Jasco CD instrument
  • Automated Applied Biosystems (AB) Procise Protein Sequencing System for N-terminal Edman degradation
  • A Perkin Applied Biosystems Procise C-terminal sequencer and a Hewlett Packard C-terminal sequencer
  • Dionex AAA Direct amino acid analyzer
  • HPLC systems suitable for narrow-bore and microcapillary chromatography and equipped for detection of peptides at 214 nm as well as variable wavelength fluorescence detection
  • Pharmacia FPLC for protein purification
  • Perkin-Elmer FTIR
  • Hitachi UV/VIS Spectrophotometer
  • Pharmacia BIAcoreTM System
  • PerSeptive Biosystems BioCAD/SPRINT
  • Bio-Rad scanning Densitometer
  • Three Thermo Finnigan LCQ family ion traps (two Classic and one Deca) equipped with electrospray/LC sources.
  • An Applied Biosystems Mariner electrospray (ES) Orthogonal TOF spectrometer
  • Applied Biosystems Voyager DE STR MALDI-TOF spectrometer
  • Scintillation and gamma counters
  • Wallac Micro Beta counter
  • Tomtec 96-well plate harvester
 

Lab Members and Alumni

Lab Members

 
Current Lab Members

Shannon Maldonado
Senior Administrative Analyst
 
Ramir Vega
Research Associate
 
Grace Aldana-Masangkay, Ph.D.
Research Fellow
 
Aileen Alontaga, Ph.D.
Research Fellow
 
Nigus D Ambaye, Ph.D.
Research Fellow

Chih-Hong Chen, Ph.D.
Research Fellow

Li Du, Ph.D.
Research Fellow
 
Yi-Jia Li, Ph.D.
Staff Scientist
 
Alumni

Postdoctoral fellows
Yate-Ching Yuan, Ph.D.
Director of the Bioinformatic Core Facility at Beckman Research Institute of City of Hope

Maria Victoria Botuyan, Ph.D.
Staff scientist at Mayo Clinic, MN, USA

Jerry Hu, Ph.D.
Manager, Materials Research Laboratory Spectroscopy Facility, UC Santa Barbara

Donghai Lin, Ph.D.
Professor at Shanghai Institute of Materia Medica, Chinese Academy of Sciences. 

Suhkmann Kim, Ph.D.
Associate Professor at Pusan National University, Korea. 

Sheng Cai, Ph.D.
Director of the NMR laboratory at Marquette University, Wisconsin, USA

Lingyang Zhu, Ph.D.
Senior Scientist, Array BioPharma Inc. Boulder, CO

Thomas Wilkinson, Ph.D.
Staff Scientist, UCLA

Xuanjun Ai, Ph.D.
Postdoctoral fellow with Dr. Charalampos Kalodimos at Rutgers University
 
Ikenna Madu, Ph.D.
Scientist Kineta, Inc, Seattle, WA
 
Yang Su, Ph.D.
Beijing, China
 
Jianghai Wang, Ph.D.
Senior Scientist, BostonBiochem, MA, USA
 
Yifei Li, Ph.D.
NCI at Frederick, Frederick, MD
 
Graduate students
Ziming Zhang, Ph.D. (2004)
Director of the Nuclear Magnetic Resonance Core, University of South Florida

Jing Song, Ph.D. (2006)
Jing spent two years as a postdoctoral fellow with Professor Timothy Springer at Harvard Medical School, and now is group leader at BioDuro.

Khue Truong, Ph.D. (2012)
Post doctoral fellow at UCLA.

Research technicians
Qin Liu, M.S., Biomolecular NMR Facility manager, Department of Biochemistry, University of Western Ontario, Canada

Candace Seu, Ph.D. student, UC San Diego

Lisa Fukui, M.D/Ph.D. student, University of Illinois at Urbane Champion

Brian Lee, medical student, SUNY Stony Brook

Larry Tong, medical student, University of Nebraska

Steven Wong, medical student, UCLA
 

Agreement Download

Yuan Chen, Ph.D. NvMap Agreement Download

Academic (nonprofit) License Agreement
 
Please send two signed originals of the license agreement to:
 
City of Hope
1500 East Duarte Road
Duarte, California 91010
Attn.:  Director, Office of Technology Licensing
Fax: 626-301-8175
 
With a copy to:
 
Dr. Yuan Chen
Department of Molecular Medicine
City of Hope
1500 East Duarte Road
Duarte, California 91010
Fax: 626-301-8186
 
Industry License Agreement
 
For more information please contact:
 
Matthew Grunseth, M.B.S.
Technology Licensing Manager
mgrunseth@coh.org
 
Our Scientists

Our research laboratories are led by the best and brightest minds in scientific research.
 

Beckman Research Institute of City of Hope is internationally  recognized for its innovative biomedical research.
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and professional education.
Learn more about City of Hope's institutional distinctions, breakthrough innovations and collaborations.
Develop new therapies, diagnostics and preventions in the fight against cancer and other life-threatening diseases.
 
Support Our Research
By giving to City of Hope, you support breakthrough discoveries in laboratory research that translate into lifesaving treatments for patients with cancer and other serious diseases.
 
 
 
 
NEWS & UPDATES
  • Rob Darakjian was diagnosed with acute lymphoblastic leukemia at just 19 years old. He began chemotherapy and was in and out of the hospital for four months. After his fourth round of treatment, he received a bone marrow transplantation from an anonymous donor. Today, he’s cancer free. In his first post, ...
  • Advanced age tops the list among breast cancer risk factor for women. Not far behind is family history and genetics. Two City of Hope researchers delving deep into these issues recently received important grants to advance their studies. Arti Hurria, M.D., director of the Cancer and Aging Research Program, and ...
  • City of Hope is extending the reach of its lifesaving mission well beyond U.S. borders. To that end, three distinguished City of Hope leaders visited China earlier this year to lay the foundation for the institution’s new International Medicine Program. The program is part of City of Hope’s strategi...
  • A hallmark of cancer is that it doesn’t always limit itself to a primary location. It spreads. Breast cancer and lung cancer in particular are prone to spread, or metastasize, to the brain. Often the brain metastasis isn’t discovered until years after the initial diagnosis, just when patients were beginning to ...
  • Blueberries, cinnamon, baikal scullcap, grape seed extract (and grape skin extract), mushrooms, barberry, pomegranates … all contain compounds with the potential to treat, or prevent, cancer. Scientists at City of Hope have found tantalizing evidence of this potential and are determined to explore it to t...
  • Most women who are treated for breast cancer with a mastectomy do not choose to undergo reconstructive surgery. The reasons for this, according to a recent JAMA Surgery study, vary. Nearly half say they do not want any additional surgery, while nearly 34 percent say breast cancer reconstruction simply isn’t imp...
  • The leading risk factor for breast cancer is simply being a woman. The second top risk factor is getting older. Obviously, these two factors cannot be controlled, which is why all women should be aware of their risk and how to minimize those risks. Many risk factors can be mitigated, and simple changes can lead...
  • All women are at some risk of developing the disease in their lifetimes, but breast cancer, like other cancers, has a disproportionate effect on minorities. Although white women have the highest incidence of breast cancer, African-American women have the highest breast cancer death rates of all racial and ethni...
  • First, the good news: HIV infections have dropped dramatically over the past 30 years. Doctors, researchers and health officials have made great strides in preventing and treating the disease, turning what was once a death sentence into, for some, a chronic condition. Now, the reality check: HIV is still a worl...
  • Screening for breast cancer has dramatically increased the number of cancers found before they cause symptoms – catching the disease when it is most treatable and curable. Mammograms, however, are not infallible. It’s important to conduct self-exams, and know the signs and symptoms that should be checked by a h...
  • Rob Darakjian was diagnosed with acute lymphoblastic leukemia at just 19 years old. He began chemotherapy and was in and out of the hospital for four months. After his fourth round of treatment, he received a bone marrow transplantation from an anonymous donor. Today, he’s cancer free.   In his previ...
  • In a single day, former professional triathlete Lisa Birk learned she couldn’t have children and that she had breast cancer. “Where do you go from there?” she asks. For Birk, who swims three miles, runs 10 miles and cycles every day, the answer  ultimately was a decision to take control of her cancer care. Afte...
  • More and more people are surviving cancer, thanks to advanced cancer treatments and screening tools. Today there are nearly 14.5 million cancer survivors in the United States. But in up to 20 percent of cancer patients, the disease ultimately spreads to their brain. Each year, nearly 170,000 new cases of brain ...
  • Cancer cells are masters of survival. Despite excessive damage to their most basic workings and the constant vigilance of the body’s immune system, they manage to persevere. Much of this extraordinary ability to survive falls under the control of proteins bearing the name STAT, short for signal transducer and a...
  • One person receives the breast cancer diagnosis, but the cancer affects the entire family. Couples, in particular, can find the diagnosis and treatment challenging, especially if they have traditional male/female communication styles. “Though every individual is unique, men and women often respond differently d...